📅 PUBMED DAILY TRIAGE — 2026-05-24 (Sunday)

Window: 2026-05-23T09:00Z → 2026-05-24T09:00Z (CRDT)
Topics scanned: 10 | Articles reviewed: ~86 candidates | Evaluated in depth: 17
High priority: 2 | Standard: 13 | Low/archive: 2 | Unsolicited finds: 1
Run status: ✅ SUCCESS

🔴🟠 HIGH PRIORITY (Score ≥8 or EARLY_CANCER_DETECTION/NOVEL_TREATMENT flag)

Novel therapeutics: immunotherapy, CAR-T, targeted therapy

TR-2026-05-24-001 · PMID 42177178 · Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells · 8/10 · 🟠 NOVEL_TREATMENT
→ Nat Commun (Schett group, Erlangen; CASTLE study). Skin biopsies from SSc patients treated with CD19-CAR T cells showed structural regeneration: dermal papillae recovery, fibroblast population normalization, and vascular repair — the first mechanistic evidence that B cell depletion via CAR-T can reverse previously considered irreversible fibrotic remodeling in a severe autoimmune rare disease.

Early cancer detection (liquid biopsy, ctDNA, cfDNA)

TR-2026-05-24-002 · PMID 42177197 · WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design · 7/10 → HIGH · 🔴 EARLY_CANCER_DETECTION
→ NPJ Breast Cancer (Esserman/UCSF). Cohort design paper for the landmark WISDOM pragmatic RCT (n=46,403, diverse nationwide US cohort). 89% of non-randomized participants self-selected risk-based screening, demonstrating strong real-world feasibility and preference for precision screening over annual mammography. Note: design paper only — efficacy outcomes not yet reported.

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)

• TR-2026-05-24-003 · PMID 42177352 · SCRUM-Japan MONSTAR3 hematology cohort: nationwide multi-omics precision medicine platform · 7/10 · Genomics/Precision Medicine — IJCO; first nationwide Japan multi-omics (WES/WTS/spatial/proteomics/metabolomics/MRD) platform for hematologic malignancies; 400 pts, enrollment Dec 2024
• TR-2026-05-24-007 · PMID 42177127 · PFS as OS surrogate in MCL: trial-level analysis · 6/10 · Treatment Innovation — CLML; 16 phase III trials, n=5996; R2=0.75 moderate surrogacy, STE HR≤0.59 required for reliable OS prediction
• TR-2026-05-24-008 · PMID 42177138 · Telomere biology disorders in developing countries · 6/10 · Diagnostics | 🟡 UNDERSERVED_POPULATION — Semin Hematol; practical LMIC algorithms for TBD diagnosis/management using serial CBC and clinical red flags; androgen therapy as accessible disease-modifying option
• TR-2026-05-24-012 · PMID 42177276 · TMSB4X in TIM3 hypermethylation and CD8+ T cell exhaustion in DLBCL · 5/10 · Genomics/Precision Medicine — Sci Rep; TMSB4X loss → epigenetic TIM3 dysregulation → T cell exhaustion; potential ICB response biomarker in DLBCL

CBC-based diagnostics and ML in hematology

(Best record for this topic shares with hematologic malignancies topic above)

• TR-2026-05-24-008 · PMID 42177138 · See above (serial CBC as core diagnostic tool for TBDs in LMICs) · 6/10
• No dedicated CBC+ML articles found this run (4 candidates total; 0 HIGH; CBC/ML topic remains low-yield for consecutive runs)

Early cancer detection (liquid biopsy, ctDNA, cfDNA)

• TR-2026-05-24-005 · PMID 42177374 · ctDNA biomarker utility in neoadjuvant ICI for resectable melanoma · 6/10 · Diagnostics — Ann Surg Oncol (MGH); Signatera ctDNA correlated with major pathologic response; limited resection comparable to TLND; n=76 (ctDNA n=22)
• TR-2026-05-24-011 · PMID 42177570 · Cervical cancer screening among HIV-positive women in conflict-affected Tigray, Ethiopia · 6/10 · Early Detection | 🟡 UNDERSERVED_POPULATION — J Health Popul Nutr; 18.9% VIA+ rate in n=2004; highest-need setting (HIV + conflict + LMIC)

AI/ML in clinical diagnostics and imaging

• TR-2026-05-24-004 · PMID 42176864 · Longitudinal plasma proteomics predicts radiation pneumonitis in lung cancer (validated n=320) · 7/10 · Diagnostics | 🟢 NEAR_TERM_IMPLEMENTABLE — IJROBP; 4-protein core (PROZ, SERPINA7, SERPINA6, HAGH) validated in independent 320-patient cohort; independent of dosimetric parameters
• TR-2026-05-24-009 · PMID 42177174 · Explainable ML identifies features/thresholds for immunotherapy response · 6/10 · Diagnostics — Sci Rep (QIMR Berghofer/Cambridge); random forest + SHAP, LAG3 + mutation burden + immune cell abundance in melanoma; n=229
• TR-2026-05-24-013 · PMID 42177597 · CT radiomics + nomogram for LN metastasis in pediatric neuroblastoma · 6/10 · Diagnostics — Cancer Imaging; AUC 0.829 validation, +21% radiologist accuracy; n=225

Precision oncology and genomic medicine

• TR-2026-05-24-006 · PMID 42177353 · VUS.Life: semantic LLM embeddings for VUS pathogenicity prediction · 6/10 · Genomics/Precision Medicine — Sci Rep (Medical College of Wisconsin); MCC 0.895-0.989 across BRCA1/2, ATM, PALB2, MYH7 (8 ACMG Tier 1 genes)

Novel therapeutics: immunotherapy, CAR-T, targeted therapy

• TR-2026-05-24-005 · PMID 42177374 · See above (ctDNA in neoadjuvant ICI melanoma) · 6/10

Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk

• TR-2026-05-24-010 · PMID 42177445 · Empagliflozin vs sitagliptin: differential effects on HOMA-IR and adropin in T2DM · 6/10 · Treatment Innovation — BMC Endocr Disord; RCT n=94 (12 weeks); SGLT2i superior for insulin resistance and HbA1c reduction; both drugs increase adropin

Aging, longevity, and population health (humans[MeSH] filter maintained)

• TR-2026-05-24-014 · PMID 42175434 · Serum cotinine and cognitive function in older adults (NHANES, n=2781) · 5/10 · Public Health — Medicine (Baltimore); L-shaped inverse association; threshold-dependent cognitive harm from tobacco exposure
• No high-priority aging/longevity articles this run (best score: 5/10)

Rare diseases with high unmet need

• TR-2026-05-24-008 · PMID 42177138 · See above (TBDs in LMICs) · 6/10 · UNDERSERVED_POPULATION

💡 UNSOLICITED FINDS

TR-2026-05-24-015 · PMID 42177490 · Deep learning SIMD phenotyping and mortality prediction (MIMIC) · 5/10 · Diagnostics — BMC Med Inform; unsupervised autoencoder + UMAP identifies 3 SIMD phenotypes; phenotype-specific XGBoost AUC 0.880. Sepsis/critical care is outside primary watchlist but AI/ML + mortality prediction is high-signal. Requires external validation before clinical translation.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 7
• Treatment Innovation: 4
• Genomics/Precision Medicine: 3
• Early Detection: 2
• Public Health: 2

By evidence maturity:

• Validated: 3 (PMID 42177197, 42177178, 42177127)
• Exploratory: 12
• Potentially Practice-Changing: 0

By watchlist topic (reviewed / kept ≥5 / highest score):

By source type: peer_reviewed 15 | preprint 0

Topics with zero 8+ articles this run: Hematologic malignancies, CBC/ML, AI/ML diagnostics, Precision oncology, Cardiometabolic, Aging/longevity, Rare diseases, Sentinel

🔧 RUN NOTES

• Window expansion: Not triggered (>5 relevant records found)
• CBC/ML hematology: 4 candidates returned; 0 HIGH for 5+ consecutive runs with this query. Topic continues to return sparse, non-specialized results. Recommend query redesign (e.g., explicitly targeting morphology AI, differential count automation, CBC pattern recognition papers) at next run.
• AI/ML diagnostics: 186 total results; remains highest-volume topic. Top 10 reviewed — 0 HIGH for 4+ consecutive runs. Topic yields high STANDARD volume. Consider topic-level alert threshold recalibration.
• Aging/longevity: humans[MeSH] filter maintained per 2026-05-04 directive; 17 results (manageable volume, no animal noise). Highest score: 5/10 this run.
• Sunday volume: Moderate. Hematologic topic (31 results) and novel therapeutics (59) have lower weekend indexing volume vs. weekday peaks (~80-100 and ~120+ respectively).
• Stud Health Technol Inform cluster: Multiple MEDINFO 2025 conference proceedings indexed this window (rare disease, health informatics cluster). Conference-level work scored conservatively (cap applied).
• PMID 42177178 (CD19-CAR T in SSc): This is a landmark result; watch for corresponding CASTLE trial clinical outcomes paper. Schett/Mackensen group at Erlangen has been leading breakthrough CAR-T in autoimmune disease work.
• Rolling 7-day topics consistently producing 0 HIGH: CBC/ML hematology (5+ days), Aging/longevity (3+ days per recent state); AI/ML diagnostics (4+ days).